azd9833
Showing 1 - 8 of 8
ER+, HER2-, Metastatic Breast Cancer Trial in China (AZD9833, AZD9833 with palbociclib, AZD9833 with everolimus)
Recruiting
- ER+, HER2-, Metastatic Breast Cancer
- AZD9833
- +2 more
-
Beijing, China
- +5 more
Jan 13, 2023
ER+ HER2- Advanced Breast Cancer Trial in Spain, United Kingdom, United States (AZD9833, AZD9833 with palbociclib, AZD9833 with
Recruiting
- ER+ HER2- Advanced Breast Cancer
- AZD9833
- +4 more
-
Aurora, Colorado
- +16 more
Aug 22, 2022
ER+ HER2- Advanced Breast Cancer Trial in Chuo-ku, Kashiwa, Koto-ku (AZD9833)
Active, not recruiting
- ER+ HER2- Advanced Breast Cancer
- AZD9833
-
Chuo-ku, Japan
- +2 more
Jan 24, 2023
HER2-negative Breast Cancer Trial in Georgia, Mexico, United Kingdom (AZD9833)
Recruiting
- HER2-negative Breast Cancer
- AZD9833
-
Batumi, Georgia
- +18 more
Jan 13, 2023
Healthy Volunteers Trial in Long Beach, Berlin (AZD9833, Midazolam, Omeprazole)
Recruiting
- Healthy Volunteers
- AZD9833
- +4 more
-
Long Beach, California
- +1 more
Jul 26, 2022
Advanced ER-Positive HER2-Negative Breast Cancer Trial in Worldwide (AZD9833, Fulvestrant)
Active, not recruiting
- Advanced ER-Positive HER2-Negative Breast Cancer
- AZD9833
- Fulvestrant
-
Birmingham, Alabama
- +94 more
Jan 31, 2023
ER-Positive HER2-Negative Breast Cancer Trial in Worldwide (AZD9833, AZD9833 Placebo, Anastrozole)
Recruiting
- ER-Positive HER2-Negative Breast Cancer
- AZD9833
- +8 more
-
Phoenix, Arizona
- +215 more
Aug 4, 2022
ER-Positive HER2-Negative Breast Cancer Trial in Worldwide (AZD9833, Anastrozole, Anastrozole )
Recruiting
- ER-Positive HER2-Negative Breast Cancer
- AZD9833
- +5 more
-
Mobile, Alabama
- +285 more
Jan 28, 2022